ATE444950T1 - Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid - Google Patents

Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid

Info

Publication number
ATE444950T1
ATE444950T1 AT06718295T AT06718295T ATE444950T1 AT E444950 T1 ATE444950 T1 AT E444950T1 AT 06718295 T AT06718295 T AT 06718295T AT 06718295 T AT06718295 T AT 06718295T AT E444950 T1 ATE444950 T1 AT E444950T1
Authority
AT
Austria
Prior art keywords
hydrochloride
dimethyladamantan
amino
producing
crystalline form
Prior art date
Application number
AT06718295T
Other languages
English (en)
Inventor
Valeriano Merli
Silvia Mantovani
Paola Daverio
Stefano Bianchi
Alessandro Spreafico
Original Assignee
Teva Pharm Fine Chemicals Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharm Fine Chemicals Srl filed Critical Teva Pharm Fine Chemicals Srl
Application granted granted Critical
Publication of ATE444950T1 publication Critical patent/ATE444950T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06718295T 2005-01-11 2006-01-11 Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid ATE444950T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64295705P 2005-01-11 2005-01-11
US67759905P 2005-05-03 2005-05-03
PCT/US2006/001204 WO2006076562A1 (en) 2005-01-11 2006-01-11 Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride

Publications (1)

Publication Number Publication Date
ATE444950T1 true ATE444950T1 (de) 2009-10-15

Family

ID=36282949

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06718295T ATE444950T1 (de) 2005-01-11 2006-01-11 Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid

Country Status (12)

Country Link
US (2) US20060173215A1 (de)
EP (2) EP1836154A1 (de)
AT (1) ATE444950T1 (de)
CA (2) CA2591487A1 (de)
DE (1) DE602006009619D1 (de)
ES (1) ES2334579T3 (de)
HR (1) HRP20090676T1 (de)
IL (2) IL183244A0 (de)
MX (2) MX2007007301A (de)
PT (1) PT1836157E (de)
SI (1) SI1836157T1 (de)
WO (2) WO2006076560A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050833A1 (it) 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
WO2007132476A2 (en) * 2006-05-15 2007-11-22 Matrix Laboratories Limited A process for the preparation of memantine hydrochloride
MX2008016568A (es) * 2006-07-05 2009-01-19 Teva Pharma Composiciones farmaceuticas de memantina.
CN101038280B (zh) * 2007-04-11 2010-09-15 山东省医药工业研究所 一种盐酸美金刚中有关物质的hplc-elsd测定方法
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2373612B1 (de) 2008-12-17 2013-04-17 Merz Pharma GmbH & Co. KGaA Verfahren zur herstellung von memantin
EP2555616A4 (de) * 2010-04-08 2014-04-02 Hetero Research Foundation Verfahren zur herstellung von memantin-hydrochlorid
AU2011316565A1 (en) 2010-10-12 2013-05-02 Cerecor Inc. Antitussive compositions comprising memantine
CN102875387A (zh) * 2012-10-23 2013-01-16 滨州泓瑞医药科技有限公司 一种盐酸金刚烷胺的制备工艺
CN104936942A (zh) * 2013-01-23 2015-09-23 三菱瓦斯化学株式会社 美金刚胺的制造工艺
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
IL303255A (en) 2015-12-30 2023-07-01 Corium Inc Systems and methods for long term transdermal administration
JP7174632B2 (ja) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス
KR102406536B1 (ko) 2016-07-27 2022-06-08 코리움, 인크. 도네페질 경피 전달 시스템
WO2018022814A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
JP2019156756A (ja) * 2018-03-13 2019-09-19 宇部興産株式会社 １−アミノ−３，５−ジメチルアダマンタン塩酸塩の結晶
EP3843702B1 (de) 2019-05-31 2023-07-05 Tecnimede, Sociedade Técnico-Medicinal, SA Festdosiskombination mit schneller freisetzung von memantin und donepezil
CN111909041B (zh) * 2020-08-12 2023-06-16 山东罗欣药业集团恒欣药业有限公司 一种用于治疗神经功能疾病药物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
CA974518A (en) 1972-04-20 1975-09-16 Merz And Co. Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
CZ282398B6 (cs) * 1994-04-13 1997-07-16 Lachema A. S. Způsob výroby 1-R1-3-R2-tricyklo(3,3,1,1,3,7)decyl-5-aminu
US5599998A (en) 1994-10-24 1997-02-04 Iowa State University Research Foundation, Inc. Method for the synthesis of adamantane amines
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
JP2002275142A (ja) 2001-03-14 2002-09-25 Daicel Chem Ind Ltd アミド化合物の製造法
CN1125033C (zh) 2001-08-29 2003-10-22 中国科学院广州化学研究所 美金刚胺盐酸盐的合成方法
CN1400205A (zh) 2002-08-30 2003-03-05 中国科学院广州化学研究所 美金刚胺盐酸盐的制备方法
CN1240668C (zh) * 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
WO2005069742A2 (en) * 2003-12-10 2005-08-04 Sun Pharmaceutical Industries Limited Crystal form ii of memantine hydrochloride
WO2005062724A2 (en) 2003-12-31 2005-07-14 Sun Pharmaceutical Industries Limited Novel process for the preparation of aminoadamantane derivatives
WO2007132476A2 (en) 2006-05-15 2007-11-22 Matrix Laboratories Limited A process for the preparation of memantine hydrochloride

Also Published As

Publication number Publication date
EP1836157B1 (de) 2009-10-07
DE602006009619D1 (de) 2009-11-19
US20060217573A1 (en) 2006-09-28
MX2007007301A (es) 2008-02-11
PT1836157E (pt) 2009-11-24
US7462743B2 (en) 2008-12-09
EP1836154A1 (de) 2007-09-26
SI1836157T1 (sl) 2009-12-31
IL183244A0 (en) 2007-08-19
EP1836157A1 (de) 2007-09-26
CA2591487A1 (en) 2006-07-20
CA2591666A1 (en) 2006-07-20
ES2334579T3 (es) 2010-03-12
IL183237A0 (en) 2007-08-19
MX2007007302A (es) 2008-02-11
HRP20090676T1 (hr) 2010-01-31
WO2006076562A1 (en) 2006-07-20
WO2006076560A1 (en) 2006-07-20
US20060173215A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE443038T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid
ATE445587T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
ATE544754T1 (de) Verfahren zur herstellung von ivabradinhydrochlorid
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE486841T1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
ATE486857T1 (de) Verfahren zur herstellung von telmisartan
DE502005001841D1 (de) Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten
EP1829868A4 (de) Verfahren zur herstellung von (4,5-dihydroxyisoxazol-3-yl)thiocarboxamidinsalzen
ATE430140T1 (de) Verfahren zur herstellung von ä1,4,5ü- oxadiazepinderivaten
ATA2732004A (de) Verfahren zur herstellung von anagrelid hydrochlorid
DE602005021110D1 (de) Verfahren zur herstellung von n-piperidino-1,5-diphenylpyrazol-3-carboxamid-derivaten
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
ATE512134T1 (de) Verfahren zur herstellung von 5-benzyloxy-2-(4- benzyloxyphenyl)-3-methyl-1h-indol
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
DE60234279D1 (de) Verfahren zur herstellung eines immunosuppresivums
DE60106778D1 (de) Verfahren zur herstellung von vitronectin-rezeptorantagonisten
DE602005026841D1 (de) Verfahren zur herstellung von 1,2,2,2-tetrafluor-ethyl-difluor-methylether
DE502006002029D1 (de) Verfahren zur herstellung von polyetheraminen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties